- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04007848
Cobimetinib for BRAF-wild-type or Mutated Histiocytoses (COBRAH)
Cobimetinib for BRAF-wild-type or Mutated Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH Study
COBRAH is a randomized double-blind 2-steps controlled superiority trial, with 2 parallel groups.
Patients will be randomly assigned in a 2:1 ratio to receive Cobimetinib orally or placebo during the first 12-weeks step, allowing the determination of the primary criteria.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. Virtually all the patients have a somatic mutation in the RAS-RAF-MEK-ERK pathway. BRAF inhibitors are efficacious to treat BRAF-mutated patients but one third of the patients are BRAF-wild type. For these patients, preliminary data have shown an efficacy of the MEK inhibitor cobimetinib. This trial aims to evaluate the efficacy of cobimetinib for treating BRAF-wild type or mutated patients with L or R group histiocytoses.
The primary objective of the COBRAH trial is to demonstrate that the rate of objective metabolic response (complete or partial) according to PERCIST criteria is higher under Cobimetinib versus placebo.
The objective metabolic response according to PERCIST criteria (Haroche, et al. 2015) is defined by the Positron Emission Tomography (PET) response and will be used to evaluate the overall therapeutic response at month 3 (Week 12).
For PERCIST criteria, a quantitative analysis of uptake will be performed using the standard uptake value (SUV). Fitting regions of interest covering pathologic uptake will be used to define target lesions. PERCIST will be used to classify the patients as complete metabolic response, partial metabolic response (reduction of a minimum of 30% in target lesions), stable metabolic disease or progressive metabolic disease.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Service de Médecine interne - La Pitié Salpêtrière
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eligible patients should be at least 18 years of age,
- Have a histologically confirmed L or R group histiocytoses without BRAFV600E mutation detected with the use of a real-time polymerase chain reaction or with BRAFV600E mutation AND a contra-indication to BRAF inhibitors
- Have a measurable disease according to the PERCIST criteria with presence of at least one severe organ involvement (heart, vascular, central nervous system) OR a multisystemic disease with ≥3 organ involvement AND failure of a first-line treatment or contra-indication to these treatments,
- Accepting effective contraception during treatment duration (men and women childbearing potential) and 3 months after.
- Signed informed consent
Exclusion Criteria:
- Patients with severe hepatic, renal and cardiac outcomes
- Patients with myopathies at baseline
- Patients with retinal detachment at baseline
- Patients with inherited disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Patients with high bleeding risk.
- Allergies to iodized contrast media
- Simultaneous participation in another medical research
- Pregnancy or breast-feeding.
- No affiliation to the French Health Care System "sécurité sociale" OR no affiliation of European Health within the scope of Regulations (EEC) n° 1408/71 and 574/72 coordinating social security systems.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cobimetinib
Experimental group : 36 histiocytoses's patients without or with BRAF V600E will be randomised in cobimetinib group
|
Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28).
Cobimetinib is available as 20 milligrams film-coated tablets
Other Names:
|
Placebo Comparator: Placebo
Control group : 18 histiocytoses's patients without or with BRAF V600E will be randomised in the placebo group
|
Placebo will be given at the dose of 40 milligrams once a day (21 days/28).
Placebo is available as 20 milligrams film-coated tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The objective metabolic responses
Time Frame: at month 3
|
The objective metabolic responses is the percentage of patients with a complete metabolic response, partial metabolic response (reduction of a minimum of 30% in target lesions), stable metabolic disease or progressive metabolic disease according to PERCIST criteria (Haroche, et al. 2015) at Month 3. PERCIST criteria is defined by the PET response and will be used to evaluate the overall therapeutic response at month 3. For PERCIST criteria, a quantitative analysis of uptake will be performed using the standard uptake value (SUV). Fitting regions of interest covering pathologic uptake will be used to define target lesions. PERCIST will be used to classify patients metabolic response. |
at month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: every 12 weeks up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group
|
Overall survival is defined as the time between the date of randomisation and the death.
|
every 12 weeks up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group
|
Progression-free survival
Time Frame: every 12 weeks up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group
|
Progression-free survival is defined as the time between the date of randomisation and the first documented event of disease progression according to PERCIST criteria (Haroche, et al. 2015).
|
every 12 weeks up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group
|
Number of participants with adverse events as assessed by CTCAE v4.0
Time Frame: From the randomisation up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group.
|
All adverse events from clinical evaluations and laboratory measurements assessed by CTCAE v4.0
|
From the randomisation up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group.
|
Overall response of Cobimetinib (metabolic and tumor assessment)
Time Frame: From the evaluation performed just before the treatment (Day 0 for Cobimetinib group, Week 12 for Placebo group)
|
Overall response of Cobimetinib (metabolic and tumor assessment) assessed after 36 weeks of Cobimetinib treatment or until Cobimetinib stop.
|
From the evaluation performed just before the treatment (Day 0 for Cobimetinib group, Week 12 for Placebo group)
|
CRP levels
Time Frame: At Baseline, Week 12, Week 24, Week 36 and Week 48 (for Placebo group)
|
CRP levels assessed from blood samples
|
At Baseline, Week 12, Week 24, Week 36 and Week 48 (for Placebo group)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fleur Dr COHEN AUBART, APHP
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P170932J - 2018-00222-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Disease or R Group Histiocytoses
-
Chinese PLA General HospitalUnknownRefractory or Relapsed Aggressive r/r B-NHL With Huge Tumor BurdenChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingRelapsed or Refractory (R/R) Primary Central Nervous System LymphomaChina
-
Novartis VaccinesCompletedGroup B Streptococcus (GBS) DiseaseSwitzerland
-
NovartisNovartis VaccinesCompletedA Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS VaccineGroup B Streptococcus (GBS) DiseaseSwitzerland
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompletedInvasive Group B Streptococcus (GBS) DiseaseSwitzerland
-
St George's, University of LondonMRC/UVRI and LSHTM Uganda Research Unit; MU-JHU CARECompletedGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionUganda
-
St George's, University of LondonMRC/UVRI and LSHTM Uganda Research Unit; MU-JHU CAREUnknownGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionUganda
-
Health Science Center of Xi'an Jiaotong UniversityGuangzhou Women and Children's Medical CenterUnknownInvasive Group B Streptococcal DiseaseChina
-
Vanderbilt UniversityUniversity of California, IrvineCompletedCondition 1 - Educational Condition (Educational Book Group) | Condition 2 - Non-educational Condition (Non-educational Book Group) | Condition 3 - Control Condition (No-book Group)United States
Clinical Trials on Cobimetinib
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.Completed
-
University of UtahGenentech, Inc.RecruitingChronic Myelomonocytic Leukemia (CMML)United States
-
University of ArkansasGenentech, Inc.RecruitingArteriovenous Malformations (Extracranial)United States
-
ImmVira Pharma Co. LtdSuspendedMelanoma | Malignant MelanomaUnited States
-
Carl AllenBaylor College of Medicine; Genentech, Inc.; North American Consortium for HistiocytosisRecruitingHistiocytic Sarcoma | Juvenile Xanthogranuloma | Histiocytic Disorders, Malignant | Erdheim-Chester Disease | Langerhan's Cell Histiocytosis | Rosai Dorfman Disease | Neuro-Degenerative DiseaseUnited States
-
Massachusetts General HospitalGenentech, Inc.RecruitingNon-small Cell Lung CancerUnited States
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.CompletedNeoplasmsUnited States, Spain
-
Genentech, Inc.CompletedHealthy VolunteerUnited States